| ²é¿´: 1040 | »Ø¸´: 1 | |||
1006939364ľ³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
[ÇóÖú]Ëû´ïÀ·ÇµÄÀí»¯ÐÔÖÊ
|
ÇóÖúËû´ïÀ·ÇµÄÀí»¯ÐÔÖÊ£¬ÓдóÉñ°ïæ²éÒ»ÏÂÂð£¿Ä¬¿ËºÍ±´¶û˹̹µÄ¶¼¿ÉÒÔ£¬×îºÃÄܹ»ºÜÈ«¡£±ÈÈçÈܽâ¶È£¬Ëá¼îÐԵȵȣ¡Ð»Ð»![]() ![]() ![]() |
» ²ÂÄãϲ»¶
ÓжàÉÙÈËÊǽñÌì²éϵͳ֪µÀ½á¹ûµÄ£¿
ÒѾÓÐ16È˻ظ´
ÎÒ²»Àí½â£¡
ÒѾÓÐ14È˻ظ´
¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶ÓÌÖÂÛ
ÒѾÓÐ4È˻ظ´
ϵͳ²é²»µ½
ÒѾÓÐ10È˻ظ´
»ù½ð²»ÖУ¬¹²Ãã
ÒѾÓÐ3È˻ظ´
Ôõô²é°¡
ÒѾÓÐ5È˻ظ´
·¶½øÖоÙÒ»ÎĵÄÖÐÐÄ˼Ïë
ÒѾÓÐ10È˻ظ´
2026ÄêµÄ¹ú¼ÒÉç¿Æ»ù½ðÏîĿͨѶÆÀÉóµÄйæÔòÓëж¯Ïò¡¢ÐÂÌôÕ½
ÒѾÓÐ9È˻ظ´
2026¹ú×ÔÈ»º¯ÆÀ·Ñµ½ÕË
ÒѾÓÐ25È˻ظ´
2026Äê8ÔÂ25ÈÕ¹ú×ÔÈ»·Å°ñǰͻȻÊÕµ½ÁÐÈëÆÀÉóר¼ÒÓʼþ£¬ÓйØÏµÂð£¿
ÒѾÓÐ28È˻ظ´
baiyuefei
°æÖ÷ (ÎÄѧ̩¶·)
·çÑ©
- Ó¦Öú: 4643 (¸±½ÌÊÚ)
- ¹ó±ö: 46.97
- ½ð±Ò: 659206
- É¢½ð: 11616
- ºì»¨: 995
- ɳ·¢: 81
- Ìû×Ó: 69600
- ÔÚÏß: 13499.5Сʱ
- ³æºÅ: 676696
- ×¢²á: 2008-12-18
- ÐÔ±ð: GG
- רҵ: ºÏ³ÉÒ©Îﻯѧ
- ¹ÜϽ: Óлú½»Á÷
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
1006939364(Ðľ²_ÒÀÈ»´ú·¢): ½ð±Ò+40, ¸ÐлӦÖú 2015-05-24 10:07:20
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
1006939364(Ðľ²_ÒÀÈ»´ú·¢): ½ð±Ò+40, ¸ÐлӦÖú 2015-05-24 10:07:20
|
Ĭ¿Ë Tadalafil Back to search results Add to My Records Print view Monograph ID: M10427 Title: Tadalafil CAS Registry Number: 171596-29-5 CAS Name: (6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1¡ä,2¡ä:1,6]©\pyrido[3,4-b]indole-1,4-dione Additional Names: (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-[3,4-(methylenedioxy)phenyl]pyrazino[1¡ä,2¡ä:1,6]©\pyrido[3,4-b]indole-1,4-dione Manufacturer Code: GF-196960; IC-351 Trademark Names: Adcirca (Lilly); Cialis (Lilly) Molecular Formula: C22H19N3O4 Molecular Weight: 389.41 Percent Composition: C 67.86%, H 4.92%, N 10.79%, O 16.43% Standard InChI: InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1Copy Copied Standard InChIKey: WOXKDUGGOYFFRN-IIBYNOLFSA-NCopy Copied Properties White crystals from 2-propanol, mp 302-303 ¡ãC. [¦Á]D20 +71.0 (c = 1.00 in CHCl3). Very slightly sol in ethanol. Practically insol in water. References Selective type 5 cGMP phosphodiesterase (PDE-5) inhibitor. Prepn: A. C. Daugan, WO 9519978 (1995 to Glaxo); eidem, US 5859006 (1999 to ICOS); and PDE-5 inhibition: idem et al., J. Med. Chem. 46, 4525, 4533 (2003) DOI: 10.1021/jm030056e PMID: 14521414. HPLC determn in plasma: C.-L. Cheng, C.-H. Chou, J. Chromatogr. B 822, 278 (2005) DOI: 10.1016/j.jchromb.2005.06.017. Clinical pharmacokinetics: S. T. Forgue et al., Br. J. Clin. Pharmacol. 61, 280 (2005) DOI: 10.1111/j.1365-2125.2005.02553.x PMID: 16487221. Clinical comparison with sildenafil for erectile disfunction: I. Eardley et al., BJU Int. 96, 1323 (2005) DOI: 10.1111/j.1464-410X.2005.05892.x PMID: 16287454. Clinical trial in pulmonary arterial hypertension: N. Gali¨¦ et al., Circulation 119, 2894 (2009) DOI: 10.1161/CIRCULATIONAHA.108.839274 PMID: 19470885. Review of cardiovascular effects: T. Reffelmann et al., Expert Opin. Drug Saf. 7, 43-52 (2008) DOI: 10.1517/14740338.7.1.43 PMID: 18171313. Classifications Therapeutic Category: Erectile Dysfunction Treatment; Phosphodiesterase Inhibitor; Pulmonary Hypertension Treatment Keywords: In treatment of male erectile dysfunction. In treatment of pulmonary arterial hypertension. Save image Save structure Other RSC ContentPowered by ChemSpider ChemSpider Record ChemSpider Structure Search Search RSC Publications |
2Â¥2015-05-20 14:29:04










»Ø¸´´ËÂ¥
ͶƱ: